We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.13B
AUM Growth
+$109M
Cap. Flow
-$57.7M
Cap. Flow %
-5.12%
Top 10 Hldgs %
41.36%
Holding
140
New
44
Increased
20
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$38.4M
2
LLY icon
Eli Lilly
LLY
+$37.9M
3
ONCR
Oncorus, Inc.
ONCR
+$20.9M
4
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
+$19.8M
5
CCCC icon
C4 Therapeutics
CCCC
+$12.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$56.2M
2
ABBV icon
AbbVie
ABBV
+$43.2M
3
AMGN icon
Amgen
AMGN
+$28M
4
FOLD
Amicus Therapeutics
FOLD
+$20M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 67.85%
2 Technology 8.78%
3 Industrials 3.15%
4 Consumer Discretionary 1.89%
5 Communication Services 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
101
DELISTED
Sage Therapeutics
SAGE
$740K 0.07%
+8,554
New +$630K
OLMA icon
102
Olema Pharmaceuticals
OLMA
$1B
$731K 0.06%
+15,200
New +$713K
VRDN icon
103
Viridian Therapeutics
VRDN
$2.09B
$502K 0.04%
+30,497
New +$460K
GMDA
104
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$336K 0.03%
+40,000
New +$271K
IMTXW
105
DELISTED
Immatics N.V. Warrants
IMTXW
$288K 0.03%
100,000
– –
PNT
106
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$279K 0.02%
20,000
– –
CLRB icon
107
Cellectar Biosciences
CLRB
$20.5M
$182K 0.02%
292
– –
ORGS
108
DELISTED
Orgenesis Inc. Common Stock
ORGS
$161K 0.01%
3,571
-36,309
-91% -$1.75M
OTLKW
109
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$29K ﹤0.01%
129,500
– –
ADMA icon
110
ADMA Biologics
ADMA
$1.96B
– –
-1,081,292
Closed -$2.58M
ALT icon
111
Altimmune
ALT
$552M
– –
-243,000
Closed -$3.21M
AMGN icon
112
Amgen
AMGN
$208B
– –
-110,000
Closed -$28M
ARVN icon
113
Arvinas
ARVN
$518M
– –
-135,000
Closed -$3.19M
CRBP icon
114
CALL
Corbus Pharmaceuticals
CRBP
$166M
– –
-2,617
Closed -$141K
CRDF icon
115
Cardiff Oncology
CRDF
$66.5M
– –
-40,000
Closed -$568K
DPZ icon
116
Domino's
DPZ
$11.5B
– –
-16,221
Closed -$6.9M
FISV
117
Fiserv Inc
FISV
$28.8B
– –
-70,246
Closed -$7.24M
FVRR icon
118
Fiverr
FVRR
$321M
– –
-57,301
Closed -$7.96M
INZY
119
DELISTED
Inozyme Pharma
INZY
– –
-196,411
Closed -$5.16M
ITOS
120
DELISTED
iTeos Therapeutics
ITOS
– –
-250,000
Closed -$6.17M
IWP icon
121
PUT
iShares Russell Mid-Cap Growth ETF
IWP
$19.8B
– –
-147,000
Closed -$12.7M
KNSA icon
122
Kiniksa Pharmaceuticals
KNSA
$5.8B
– –
-259,990
Closed -$3.98M
LLY icon
123
CALL
Eli Lilly
LLY
$1.02T
– –
-200,000
Closed -$29.6M
LRMR icon
124
Larimar Therapeutics
LRMR
$397M
– –
-342,064
Closed -$5.19M
NRIX icon
125
Nurix Therapeutics
NRIX
$2.41B
– –
-22,480
Closed -$785K
2 3 4
5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sphera Funds Management held 140 positions worth $1.13B, up 11% from $1.02B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management withdrew a net $57.7M in Q4 2020, closing 30 positions and reducing 33 holdings. Its most notable exit was Sanofi, an estimated $56.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Bristol-Myers Squibb worth $38.8M.

  • Sphera Funds Management's largest Q4 2020 buy was Bristol-Myers Squibb: 625,000 shares worth $38.8M.
  • Sphera Funds Management added most to Eli Lilly in Q4 2020, an estimated $37.9M increase.
  • Sphera Funds Management's biggest Q4 2020 reduction was AbbVie, cutting an estimated $43.2M.
  • Sphera Funds Management fully exited Sanofi in Q4 2020, selling an estimated $56.2M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $1.13B portfolio in Q4 2020.
  • Sphera Funds Management opened 44 new positions and closed 30 in Q4 2020.
  • Sphera Funds Management's portfolio value rose 11% quarter-over-quarter to $1.13B.

Based on Sphera Funds Management's 13F filing for Q4 2020, filed 16 Feb 2021.